IDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year High – What’s Next?

Posted by Geri Gentry on Jul 6th, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $39.32 and last traded at $38.94, with a volume of 334469 shares. The stock had previously closed at $37.65.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Wall Street Zen raised IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Guggenheim lifted their target price on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $50.69.

View Our Latest Stock Report on IDYA

IDEAYA Biosciences Trading Up 2.4%

The firm has a market cap of $3.39 billion, a P/E ratio of -24.10 and a beta of -0.09. The business’s 50-day moving average is $30.62 and its two-hundred day moving average is $32.45.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. The firm’s revenue was down 39.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) earnings per share. On average, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.13 earnings per share for the current year.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently added to or reduced their stakes in the stock. GSK plc bought a new stake in IDEAYA Biosciences in the fourth quarter valued at $46,093,000. Baker BROS. Advisors LP increased its holdings in shares of IDEAYA Biosciences by 54.6% in the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after acquiring an additional 1,156,716 shares during the period. State Street Corp lifted its position in IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after purchasing an additional 893,707 shares during the last quarter. Janus Henderson Group PLC lifted its position in IDEAYA Biosciences by 11.8% in the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock valued at $248,344,000 after purchasing an additional 758,117 shares during the last quarter. Finally, First Turn Management LLC acquired a new position in IDEAYA Biosciences during the 4th quarter valued at about $25,017,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.